Use of ossein–hydroxyapatite complex in the prevention of bone loss: a review

References

• Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864–73
   PubMed Web of Science ®Google Scholar
• Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008;336:262–6
   PubMed Web of Science ®Google Scholar
• Pentti K, Tuppurainen MT, Honkanen R, et al. Use of calcium supplements and the risk of coronary heart disease in 52–62- year-old women: The Kuopio Osteoporosis Risk Factor and Prevention Study. Maturitas 2009;63:73–8
   PubMed Web of Science ®Google Scholar
• Wang TKM, Bolland MJ, van Pelt NC, et al. Relationships between vascular calcification, calcium metabolism, bone density, and fractures. J Bone Miner Res 2010;25:2777–85
   PubMed Web of Science ®Google Scholar
• Manson JE, Allison MA, Carr JJ, et al. Calcium/vitamin D supplementation and coronary artery calcification in the Women's Health Initiative. Menopause 2010;17:683–91
   PubMed Web of Science ®Google Scholar
• Lewis JR, Calver J, Zhu K, Flicker L, Prince RL. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res 2011;26:35–41
   PubMed Web of Science ®Google Scholar
• Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503–11
   PubMed Web of Science ®Google Scholar
• Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 2009;205:255–60
   PubMed Web of Science ®Google Scholar
• Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008;168:1629–37
   PubMed Web of Science ®Google Scholar
• Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008;168:1340–9
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Ewing SK, Fredman L, et al. Circulating 25- hydroxyvitamin D levels and frailty status in older women. J Clin Endocrinol Metab 2010;95:5266–73
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Blackwell TL, Cauley JA, et al. Circulating 25- hydroxyvitamin D levels and frailty in older men: the osteoporotic fractures in men study. J Am Geriatr Soc 2011;59:101–6
   PubMed Web of Science ®Google Scholar
• Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53–8
   PubMed Web of Science ®Google Scholar
• Durance R, Parsons V, Atkins C, Hamilton E, Davies C. Treatment of osteoporotic patients. A trial of calcium supplements (Ossopan) and ashed bone. Clin Trial J 1973;3:67–75
   Google Scholar
• Castelo-Branco C, Martínez de Osaba MJ, Pons F, et al. Ossein-hydroxyapatite compounds for preventing postmenopausal bone loss. Coadjuvant use with hormone replacement therapy. J Reprod Med 1999;44:241–6
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Pons F, Vicente JJ, Sanjuán A, Vanrell JA. Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial. J Reprod Med 1999;44:601–5
   PubMed Web of Science ®Google Scholar
• Stěpán JJ, Pospíchal J, Presl J, Pacovský V. Prospective trial of ossein-hydroxyapatite compound in surgically induced postmenopausal women. Bone 1989;10:179–85
   PubMed Web of Science ®Google Scholar
• Lorenc RS, Hoszowski K Tlustochowicz W. No efficacy and safety of ossein-hydrohyapatite complex (OHC) 800 mg tablets and 3200 mg sachets versus calcium carbonate in osteoporotic post menopausal women. Osteoporos Int 1998;8(Suppl 3):102 (Abstr P319)
   Google Scholar
• Rüegsegger P, Keller A, Dambacher MA. Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. Osteoporos Int 1995; 5:30–4
   PubMed Web of Science ®Google Scholar
• Ciria-Recasens M, Blanch-Rubió J, Coll-Batet M, et al. Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: a randomized, open-label, parallel-group, controlled, prospective study. Clin Drug Investig 2011;31: 817–24
   PubMed Web of Science ®Google Scholar
• Stamp TCB, Jenkins MV, Walker PG MT. Treatment of osteoporosis with MCHC compound and sodium fluoride. Int Congr Symp 1983;9:287–90
   Google Scholar
• Annefeld M, Caviezel R, Schacht E, Schicketanz KH. The influence of ossein-hydroxyapatite compound (‘Ossopan’) on the healing of a bone defect. Curr Med Res Opin 1986;10:241–50
   PubMed Web of Science ®Google Scholar
• Drivdahl RH, Howard GA, Baylink DJ. Extracts of bone contain a potent regulator of bone formation. Biochim Biophys Acta 1982;714:26–33
   PubMed Web of Science ®Google Scholar
• Kirilova IA, Fomichev NG, Podorozhnaya VT. New materials for bone grafting in view of current concepts. Hir pozvonocnika 2007;2:66–70
   Google Scholar
• Rodionova SS, Kolondaev AF, Sokolov VA, Markov SA. Experience with the use of Osteogenon in traumatology and orthopedics. Bull Traumatol Orthop 2001;4:41–6
   Google Scholar
• Faĭvishevskiĭ ML, Rodionova SS, Furtseva LN.[New calcium-containing product for complex treatment of osteoporosis]. Vopr Pitan 2001;70:32–5
   PubMedGoogle Scholar
• Schmidt KH, Wörner UM, Buck HJ. Examination of new bone growth on aluminium oxide implant contact surfaces after oral administration of ossein-hydroxyapatite compound to rats. Curr Med Res Opin 1988;11:107–15
   PubMed Web of Science ®Google Scholar
• Bugaev D, Gorbunkov V. Diagnosis and treatment of fractures of the distal radius metaepiphysis in elderly and senile age. Med New North Caucasus 2013;1:108–12
   Google Scholar
• Liu H, Peng H, Wu Y, et al. The promotion of bone regeneration by nanofibrous hydroxyapatite/chitosan scaffolds by effects on integrin-BMP/Smad signaling pathway in BMSCs. Biomaterials 2013;34:4404–17
   PubMed Web of Science ®Google Scholar
• Gul'nazarova SV, Kuznetsova OA. Ossein-hydroxyapatite complex in the treatment of patients with pseudoarthrosis of the femur and shin bones, complicated by systemic osteoporosis. Bull Traumatol Orthop Priorov 2006;2:21–4
   Google Scholar
• Kunhardt Rasch J, Montoya Romero JJ, Diáz Loya FJ, Sosa de Martínez MC.[Measurement of calcium and phosphorus levels during pregnancy and the puerperium]. Ginecol Obstet Mex 1984;52:267–70
   PubMedGoogle Scholar
• Chavassieux P, Pastoureau P, Boivin G, Delmas PD, Chapuy MC, Meunier PJ. Effects of ossein-hydroxyapatite compound on ewe bone remodeling: biochemical and histomorphometric study. Clin Rheumatol 1991;10:269–73
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Haya-Palazuelos J, Cancelo-Hidalgo MJ. Menopause and osteoporosis: usefulness of ossein-hydroxyapatite complex. In Castelo-Branco C, Haya Palazuelos J, eds. Osteoporosis and Menopause. Madrid, Spain: Ed Medica Panamericana, 2007:217–25
   Google Scholar
• Srimongkol T, Bunyaratavej N. Clinical study of efficacy of hydroxyapatite. J Med Assoc Thai 2005;88(Suppl 5):S24–6
   PubMedGoogle Scholar
• Yang X, Tare RS, Partridge KA, et al. Induction of human osteoprogenitor chemotaxis, proliferation, differentiation, and bone formation by osteoblast stimulating factor-1/pleiotrophin: osteoconductive biomimetic scaffolds for tissue engineering. J Bone Miner Res 2003;18:47–57
   PubMed Web of Science ®Google Scholar
• Lotinun S, Kiviranta R, Matsubara T, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest 2013;123:666–81
   PubMed Web of Science ®Google Scholar
• Lugli R, Bruneti G, Salvioli G. Effect of ossein-hydroxyapatite compound on back pain in the elderly. Results of a placebo-controlled trial. Clin Trials J 1990;27:141–8
   Google Scholar
• Castelo-Branco C, Ciria-Recasens M, Cancelo-Hidalgo MJ, et al. Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss: a meta-analysis. Menopause 2009;16:984–91
   PubMed Web of Science ®Google Scholar
• Nilsen KH, Jayson MI, Dixon AS. Microcrystalline calcium hydroxyapatite compound in corticosteroid-treated rheumatoid patients: a controlled study. Br Med J 1978;2:1124
   PubMed Web of Science ®Google Scholar
• Dent CE, Davies IJ. Calcium metabolism in bone disease: effects of treatment with microcrystalline calcium hydroxyapatite compound and dihydrotachysterol. J R Soc Med 1980;73:780–5
   PubMed Web of Science ®Google Scholar
• Brenton D, Dent C. Idiopathic juvenile osteoporosis. In Bickel H, Stern J, eds. Inborn Errors of Calcium and Bone Metabolism. Lancaster, UK: MTP, 1976:222–38
   Google Scholar
• Wagner JR. A 3 -year clinical evaluation of resorbable hydroxylapatite OsteoGen (HA Resorb) used for sinus lift augmentations in conjunction with the insertion of endosseous implants. J Oral Implantol 1991;17:152–64
   PubMedGoogle Scholar
• Epstein O, Kato Y, Dick R, Sherlock S. Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis. Am J Clin Nutr 1982;36:426–30
   PubMed Web of Science ®Google Scholar
• Mills TJ, Davis H, Broadhurst BW. The use of a whole bone extract in the treatment of fractures. Manit Med Rev 1965;45:92–6
   PubMedGoogle Scholar
• Khadzhiev A, Rachev E, Katsarova M, Cherveniashki S. [The results of a clinical trial of the preparation Ossopan]. Akusherstvo i Ginekol 1990;29:85–7
   PubMedGoogle Scholar
• Castelo-Branco C, Pons F, Vanrell J. Prevention of postmenopausal-related bone loss with ossein hydroxyapatite compound in healthy subjects who did not wish to use hormone replacement therapy: results of a two year prospective trial. Osteoporos Int 1998;8(Suppl 3):102 (Abstr P318)
   Google Scholar
• Fernández-Pareja A, Hernández-Blanco E, Pérez-Maceda JM, Riera Rubio VJ, Palazuelos JH, Dalmau JM. Prevention of osteoporosis: four-year follow-up of a cohort of postmenopausal women treated with an ossein-hydroxyapatite compound. Clin Drug Investig 2007;27:227–32
   PubMed Web of Science ®Google Scholar
• Pelayo I, Haya J, De la Cruz JJ, et al. Raloxifene plus ossein-hydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial. Menopause 2008;15:1132–8
   PubMed Web of Science ®Google Scholar
• Chevalley T, Rizzoli R, Nydegger V, et al. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporos Int 1994;4:245–52.
   PubMed Web of Science ®Google Scholar
• Brazier M, Fardelonne P, Bellony R, Sebert JL, Desmet G. [Fluoride bioavailability from sodium fluoride alone or in association with different calcium salts]. Eur J Drug Metab Pharmacokinet 1991;Spec No 3:161–5
   PubMedGoogle Scholar
• Varga OI, Vezikova NN, Marusenko IM, Kheĭfets LM. [Osteogenon in therapy of distal radial bone fractures in patients with secondary osteoporosis]. Ter Arkh 2007;79: 52–4
   PubMed Web of Science ®Google Scholar
• Pines A, Raafat H, Lynn AH, Whittington J. Clinical trial of microcrystalline hydroxyapatite compound (‘Ossopan’) in the prevention of osteoporosis due to corticosteroid therapy. Curr Med Res Opin 1984;8:734–42
   PubMed Web of Science ®Google Scholar
• Stellon A, Davies A, Webb A, Williams R. Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis. Postgrad Med J 1985;61:791–6
   PubMed Web of Science ®Google Scholar
• Gupta S. Ossopan in the treatment of fracture of long bones. Ind Med Gaz 1981;9:312–14
   Google Scholar
• Warnecke G. Experience with ossein-hydroxyapatite complex (Ossopan®) in musculoskeletal dísorders of pregnancy. Zeit Artz Klin Prax 1987;62:1862–3
   Google Scholar
• Grall J, Arvis P, Mention J. Etude de l'activite d'un complexe d'hydroxyapatite microcristalline (CHMC) au cours de la grossesse. Actual Thérapeutique 1984;91:82–4
   Google Scholar
• Morin P, Ameteau J, Paupardin C. Intérêt d'un extrait d'os total chez la femme enceinte. Gaz Med 1977;84:2839–43
   Google Scholar